A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

470

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: BMS-986504
DRUG: Gemcitabine
DRUG: Nab-paclitaxel
DRUG: Placebo

Sponsor

Bristol-Myers Squibb